Managed Care
NAMD Discusses Medicaid Coverage of GLP-1 Weight Loss Drugs
The National Association of Medicaid Directors addressed Medicaid coverage considerations for new anti-obesity medications in a discussion with VeryWellHealth reporters. The conversation focused on access and policy implications for Medicaid enrollees. As GLP-1 drugs like Wegovy and Zepbound gain FDA approval for weight loss, state Medicaid programs face coverage decisions affecting millions of beneficiaries. Medicaid managed care plans must navigate utilization management, prior authorization requirements, and budget impact as states determine whether and how to cover these high-cost medications.
Why it mattersState decisions on covering GLP-1 anti-obesity drugs will directly affect MCO pharmacy spend, prior authorization protocols, and member access to treatments that can cost over $1,000 monthly per patient.